Radotinib
Radotinib, and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of Y, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other tyrosine kinase Bcr-Abl inhibitors

Catalog Number | T2328 |
Alternative Name(s) | IY-5511 , Supect |
Research Area | Cytoskeletal Signaling|||Tyrosine Kinase/Adaptors|||Angiogenesis |
Molecular Formula | C27H21F3N8O |
CAS# | 926037-48-1 |
Purity | 99.70% |
SMILES | Cc1c(cc(cc1)C(=O)Nc1cc(cc(c1)n1cc(nc1)C)C(F)(F)F)Nc1nccc(n1)c1nccnc1 |
Size | 50 mg |
Supplier Page | https://www.targetmol.com/compound/Radotinib |
Additional Information | https://www.targetmol.com/datasheet/T2328 |